At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
Doravirinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers
Chelsea and Westminster NHS Foundation Trust·interventional·Posted Mar 28, 2019·Updated Sep 19, 2024
In Brief
A Phase 1 clinical trial evaluating Doravirine for Human Immunodeficiency Virus. Completed, enrolled 24 participants across 1 site.
Detailed Summary
Study to assess the pharmacokinetics of plasma doravirine once daily over 72 hours following drug intake cessation at steady-state in healthy volunteers
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus
CountriesUnited Kingdom
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedMar 2019
Enrollment StartJun 2019
Primary CompletionJul 2019
Study CompletionAug 2019
TodayJul 2026
First PostedMar 28, 2019
Enrollment StartJun 12, 2019
Primary CompletionJul 25, 2019
Study CompletionAug 6, 2019
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 7.3 years ago
Interventions
Doravirinedrug
Non-nucleoside reverse transcriptase inhibitor. Administered as film coated tablet.